Q32 Bio Inc. (QTTB)

Market Cap	310.64M
Revenue (ttm)	1.16M
Net Income (ttm)	-112.96M
Shares Out	11.93M
EPS (ttm)	-35.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,615
Open	25.53
Previous Close	26.45
Day's Range	25.20 - 26.91
52-Week Range	8.24 - 30.92
Beta	-0.11
Analysts	Buy
Price Target	47.50 (+83.33%)
Earnings Date	May 3, 2024

About QTTB

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed I...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: QTTB

Financial Performance

In 2023, Q32 Bio's revenue was $1.16 million, a decrease of -63.97% compared to the previous year's $3.21 million. Losses were -$112.96 million, 2157.0% more than in 2022.

Financial numbers in USD

Analyst Forecast

According to 2 analysts, the average rating for QTTB stock is "Buy." The 12-month stock price forecast is $47.5, which is an increase of 83.33% from the latest price.

Price Target

$47.5

(83.33% upside)

Analyst Consensus: Buy